Hospital Universitari de Bellvitge
bellvitgehospital.catLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
120
Active
33
Phase 3
5
Total enrollment
11,147,601
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| GLP-1 Receptor Agonist | — | — | — | — | — | 1 | |
| Oral Progestins | — | — | — | — | — | 1 | |
| Lacosamide | — | — | — | — | — | 1 |
Next readouts
- 2026-12
- 2031-04
Top conditions
- Breast Cancer7
- Heart Failure6
- Morbid Obesity5
- Pancreatic Cancer5
- Biliary Tract Neoplasms5
- Acute Kidney Injury4
- Malignant Biliary Obstruction4
- Obesity4
Frequently asked questions about Hospital Universitari de Bellvitge
- How many clinical trials does Hospital Universitari de Bellvitge have on ClinicalTrials.gov?
- Hospital Universitari de Bellvitge is listed as the lead sponsor on 120 clinical trials in ClinicalTrials.gov, 33 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Hospital Universitari de Bellvitge's trials are in Phase 3?
- 5 of Hospital Universitari de Bellvitge's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Hospital Universitari de Bellvitge focus on?
- Hospital Universitari de Bellvitge's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Heart Failure, Morbid Obesity, Pancreatic Cancer, Biliary Tract Neoplasms.
- When are Hospital Universitari de Bellvitge's next clinical trial readouts?
- Hospital Universitari de Bellvitge has 2 upcoming primary-completion readouts tracked here; the soonest is “Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia”, expected around 2026-12.